VAERS Explorer
Back to explore

Report #2883709

Received Feb 2, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
1.3 yrs
State
LA
Recovered
Unknown
Vaccinated
Jan 27, 2026
Onset
Jan 27, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
DTAPIPVHIBDTAP + IPV + HIB (PENTACEL)SANOFI PASTEUR4UK367AAOT / LL

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

administering DTaP/IPV with sterile water and Hib component was not used and reconstituted with no reported adverse event; Initial information received on 29-Jan-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves a 16 months old female patient who received DTAP/IPV of diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine [Pentacel (VERO)] with sterile water and HIB component was not used and reconstituted with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included pneumococcal vaccine CONJ 20V (CRM197) (Prevnar 20) for Immunisation. On 27-Jan-2026, the patient received 0.5 ml of dose 4 of diphtheria/tetanus/5 hybrid AC pertussis/IPV(VERO)/HIB(PRP/T) vaccine Powder and suspension for suspension for injection with standard strength (expiry date- 31-MAR-2027 and lot UK367AA) via unknown route in the left vastus lateralis (left thigh) for Immunization with sterile water and HIB component was not used and reconstituted with no reported adverse event (single component of a two-component product administered) (latency- same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Other medications

PREVNAR 20